Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Intracellular Therapies

Request full access

Therapeutics for central nervous system disorders

New York City, United StatesFounded 2002Biotech & Life Sciences

About Intracellular Therapies

Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on developing innovative treatments for neuropsychiatric and neurologic disorders. The company operates in the healthcare sector, targeting patients suffering from conditions such as schizophrenia and bipolar depression. Its flagship product, CAPLYTA, is an FDA-approved medication designed to address these mental health issues. The company serves healthcare providers, patients, and caregivers, aiming to improve the quality of life for individuals affected by these disorders.

Intra-Cellular Therapies employs a business model centered around the discovery, development, and commercialization of novel therapeutics. Revenue is primarily generated through the sale of CAPLYTA and other investigational compounds in their pipeline. The company leverages its extensive expertise in drug development to bring new treatments from the research phase to market readiness.

Key markets include the United States and other regions with significant demand for advanced neuropsychiatric treatments. The company continuously invests in research and development to expand its portfolio and address unmet medical needs.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2014
Outcome tier
Unicorn$1–10B valuation tierThoroughbred$100M+ revenue

Intracellular Therapies in the New York City ecosystem

Live from Dealroom

The Intracellular Therapies office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

Series A1 investor entered at this stage

  • Alafi Capital

Series B and later1 investor entered at this stage

  • Tech Council Ventures
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States99.7%
🇵🇰 Pakistan0.2%
2 countries shown
Web traffic by country
5.3K monthly visits
across markets
🇺🇸 United States79.2%
🇮🇳 India15.1%
🇦🇺 Australia5.7%
Top 3 markets shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Intracellular Therapies on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Intracellular Therapies on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.